[go: up one dir, main page]

WO2023141334A3 - Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders - Google Patents

Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders Download PDF

Info

Publication number
WO2023141334A3
WO2023141334A3 PCT/US2023/011351 US2023011351W WO2023141334A3 WO 2023141334 A3 WO2023141334 A3 WO 2023141334A3 US 2023011351 W US2023011351 W US 2023011351W WO 2023141334 A3 WO2023141334 A3 WO 2023141334A3
Authority
WO
WIPO (PCT)
Prior art keywords
betamethasone
mycophenolic acid
pharmaceutical compositions
treatment
ocular disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/011351
Other languages
French (fr)
Other versions
WO2023141334A2 (en
Inventor
Kamran Hosseini
Richard Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surface Ophthalmics Inc
Original Assignee
Surface Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/582,627 external-priority patent/US20220143075A1/en
Application filed by Surface Ophthalmics Inc filed Critical Surface Ophthalmics Inc
Priority to JP2024543835A priority Critical patent/JP2025513090A/en
Priority to CN202380013103.9A priority patent/CN118510520A/en
Priority to EP23743806.4A priority patent/EP4469059A2/en
Publication of WO2023141334A2 publication Critical patent/WO2023141334A2/en
Publication of WO2023141334A3 publication Critical patent/WO2023141334A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions and methods for treating ocular disorders in a subject, which include betamethasone or a pharmaceutically acceptable salt thereof at a concentration of 0.01% w/w to 0.08% w/w, mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 0.30% w/w, or both betamethasone and mycophenolic acid or their salts.
PCT/US2023/011351 2022-01-24 2023-01-23 Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders Ceased WO2023141334A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024543835A JP2025513090A (en) 2022-01-24 2023-01-23 Pharmaceutical Compositions of Mycophenolic Acid and/or Betamethasone for the Treatment of Eye Diseases - Patent application
CN202380013103.9A CN118510520A (en) 2022-01-24 2023-01-23 Pharmaceutical composition of mycophenolic acid and/or betamethasone for the treatment of ocular diseases
EP23743806.4A EP4469059A2 (en) 2022-01-24 2023-01-23 Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17/582,627 2022-01-24
US17/582,627 US20220143075A1 (en) 2017-09-25 2022-01-24 Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US202263317770P 2022-03-08 2022-03-08
US63/317,770 2022-03-08
US202263402704P 2022-08-31 2022-08-31
US63/402,704 2022-08-31
US202263415419P 2022-10-12 2022-10-12
US63/415,419 2022-10-12

Publications (2)

Publication Number Publication Date
WO2023141334A2 WO2023141334A2 (en) 2023-07-27
WO2023141334A3 true WO2023141334A3 (en) 2023-09-21

Family

ID=87349251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/011351 Ceased WO2023141334A2 (en) 2022-01-24 2023-01-23 Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders

Country Status (3)

Country Link
EP (1) EP4469059A2 (en)
JP (1) JP2025513090A (en)
WO (1) WO2023141334A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007709A (en) 2018-12-27 2021-12-15 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease.
CN117979951A (en) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 Use of chondroitin sulfate for relieving eye pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20150190407A1 (en) * 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
WO2020139525A1 (en) * 2018-12-27 2020-07-02 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20200289455A1 (en) * 2017-09-25 2020-09-17 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2021124301A1 (en) * 2019-12-20 2021-06-24 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
WO2022240598A1 (en) * 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101332180A (en) * 2008-08-01 2008-12-31 北大方正集团有限公司 Mycophenolic acid eye drops and preparation method thereof
CN104083323B (en) * 2014-06-27 2016-06-08 新乡医学院 Comprise the eye suspension of tobramycin and Betamethasone Valerate
JP6871548B2 (en) * 2016-11-24 2021-05-12 国立大学法人東北大学 Composition for maintaining filter vesicles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20150190407A1 (en) * 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
US20200289455A1 (en) * 2017-09-25 2020-09-17 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2020139525A1 (en) * 2018-12-27 2020-07-02 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
WO2021124301A1 (en) * 2019-12-20 2021-06-24 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
WO2022240598A1 (en) * 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain

Also Published As

Publication number Publication date
JP2025513090A (en) 2025-04-23
WO2023141334A2 (en) 2023-07-27
EP4469059A2 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
WO2023141334A3 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
JP7447176B2 (en) Eye drops containing diquafosol
EP4631944A3 (en) Rimegepant for cgrp related disorders
IL248745B (en) S-2-amino-3-methyl -butyric acid (2r, 3r, 11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2'1-a]isoquinolin-2yl ester for use in treating tarditive dyskenesia
MX2023012013A (en) Treatment of essential tremor.
JP2020509085A5 (en)
AU2017261303A1 (en) Ophthalmic compositions
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
KR20120050473A (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
EP1192949A4 (en) ACIDS WITH CHYMASEINHIBITORS AS EFFECTIVE MEANS FOR THE PREVENTION OR TREATMENT OF FIBROSIS
WO2023250247A3 (en) R-mdma crystal forms
WO2016171152A1 (en) Therapeutic agent, improving agent, and preventative agent for corneal disorders
MY205498A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
KR20220061147A (en) Methods for alleviating pterygium-related concerns about the appearance of the eye
US20100227868A1 (en) Treatment methods with brimonidine
WO2024010045A1 (en) Pain suppressant
EP4108240A3 (en) Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3
Hedges et al. A double-blind comparison of meptazinol with pethidine in postoperative pain
JP2016503043A (en) Use of pidothymod to treat psoriasis
CA3169401A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
CN106507666A (en) Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the treatment of sarcoidosis
WO2024211252A3 (en) Modulators of trpml, their compositions and methods of use
WO2024173750A3 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent
WO2024050516A3 (en) Varenicline related compounds and methods for treating diseases and conditions including tobacco use disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743806

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380013103.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2024543835

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023743806

Country of ref document: EP

Effective date: 20240826

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743806

Country of ref document: EP

Kind code of ref document: A2